Hao Xie et al reported that after surgical resection in pancreatic adenocarcinoma, to achieve the best survival, the level of RRM1 expression may be used to stratify patients to receive either adjuvant gemcitabine or non-gemcitabine adjuvant therapy. This evidence concerns the gene RRM1 and pancreatic adenocarcinoma.